What is CareDx's gross profit margin?

What does CareDx do and what are its main business segments?

What were the key takeaways from CareDx’s earnings call?

Did CareDx beat or miss consensus estimates last quarter?

What factors drove the changes in CareDx's revenue and profit?

What is the market's earnings forecast for CareDx next quarter?

What were the key takeaways from CareDx's earnings call?

What guidance did CareDx's management provide for the next earnings period?

- **Revenue Growth**: Q3 2025 revenue up 21% YoY to $100.1M, with Testing Services leading at +19%.
- **New Product Momentum**: HistoMap Kidney (Q2 2026 launch) and AlloSeq Tx11 enhance diagnostic offerings.
- **Operational Excellence**: 20% order turnaround time reduction via EPIC, 124% cash collections vs. Testing Services revenue.
- **Guidance Raise**: 2025 revenue updated to $372M-$376M, EBITDA to $35M-$39M, reflecting strong RCM performance.

**【CEO Summary Section】**
- **Record Q3 Performance**: Total revenue of $100.1 million, up 21% YoY, driven by Testing Services ($72.2M, +19%), Patient & Digital Solutions ($15.4M, +30%), and Lab Products ($12.5M, +22%).
- **New Product Launches**: HistoMap Kidney (commercial launch Q2 2026) and AlloSeq Tx11 (enhanced HLA typing solution) announced at medical conferences.
- **Strategic Hires**: Appointment of Dr. Jeff Teuteberg as CMO and Suresh Gunasekaran to the Board, strengthening clinical and customer insights.
- **Operational Wins**: 20% reduction in order turnaround time via EPIC integration and 124% cash collections vs. Testing Services revenue.
- **Guidance Update**: Full-year 2025 revenue raised to $372M-$376M, EBITDA to $35M-$39M.

**【CFO Financial Commentary】**
- **Financial Highlights**: Non-GAAP gross margin 70.9%, operating expenses down 5% YoY to 58% of revenue. Adjusted EBITDA $15.3M (+108% YoY).
- **Cash Flow Strength**: $119M cash collections (including $5.9M prior-period claims), ending Q3 with $194.2M cash.
- **Q4 Outlook**: Revenue $101M-$105M, ASP $1,400-$1,420 (inclusive of $4M-$6M collections benefit).

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

CDNA

CDNA fundamentals

You can ask Aime